{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-049683","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2023-09-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.068172+00:00","generated_at":"2026-06-10T09:16:51.496449+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BridgeBio Pharma raises $250M in PIPE financing led by Qatar Investment Authority","bullets":["Issues 9,167,723 shares at $27.27/share (Sept 22 close); gross proceeds ~$250M.","Financing led by QIA, with participation from four large US investment management firms.","Proceeds to fund acoramidis launch, Phase 3 readouts in achondroplasia, LGMD2I, ADH1, and general corporate purposes.","PIPE expected to close Sept 27, 2023, subject to customary conditions.","Company also exploring additional less dilutive financing options to optimize cost of capital."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-049683","json":"https://secwatch.observer/filing/0000950170-23-049683.json","markdown":"https://secwatch.observer/filing/0000950170-23-049683.md","text":"https://secwatch.observer/filing/0000950170-23-049683.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000095017023049683/0000950170-23-049683-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000095017023049683/bbio-20230925.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T09:16:51.496449+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"89e39e31af8478a35c9ba8d28a7799d777b7d47e","claim":"BridgeBio Pharma, Inc. entered into Purchase Agreement with certain accredited investors valued at approximately $250 million (effective 2023-09-25).","evidence_excerpt":"On September 25, 2023, BridgeBio Pharma, Inc. (the “Company”) and certain accredited investors (each an “Investor” and collectively, the “Investors”) entered into a securities purchase agreement (the “Purchase Agreement”) pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of 9,167,723 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $27.27 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017023049683/0000950170-23-049683-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"approximately $250 million"},{"label":"Effective","value":"2023-09-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}